CVSA · Covista Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $521.7M | fiscal year | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 26.7% | the fiscal year ended June 30, 2026 | — |
|
|
|||
| Adjusted net income (non-GAAP) non-GAAP | $294.7M | Year Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income (GAAP) 251.57M
+6.33M Restructuring expense
+11.22M Amortization of acquired intangible assets
+18.56M Strategic advisory costs
+4.81M Loss on debt extinguishment, litigation reserve, asset impairments, loss on assets held for sale, and debt modification costs
-3.29M Tax benefit due to change in unrecognized tax benefits
-10.31M Income tax impact on non-GAAP adjustments
+15.81M Loss (income) from discontinued operations
= Adjusted net income (non-GAAP) 294.7M
|
|||
| Adjusted operating income (non-GAAP) non-GAAP | $419.49M | Year Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating income (GAAP) 383.38M
+6.33M Restructuring expense
+11.22M Amortization of acquired intangible assets
-5.55M Litigation reserve
+6.44M Asset impairments
+18.56M Strategic advisory costs
-490K Loss on assets held for sale
-712K Debt modification costs
= Adjusted operating income (non-GAAP) 419.49M
|
|||
| Adjusted operating margin (non-GAAP) non-GAAP | 21.5% | Year Ended June 30, 2026 | — |
| Free cash flow (non-GAAP) non-GAAP | $393.1M | Q4 FY2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities-continuing operations (GAAP) $470.8M
-$77.7M Capital expenditures
= Free cash flow (non-GAAP) $393.1M
|
|||
| Medical and Veterinary enrolled students (average) | 5,250 | fiscal year | — |
| Net debt (non-GAAP) non-GAAP | $266.68M | Year Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Total long-term debt principal $673M
-$406.32M Less: Cash and cash equivalents
= Net debt (non-GAAP) $266.68M
|
|||
| Total Students (Chamberlain) | 39,501 | Three Months Ended June 30, 2026 | — |
| Total Students (Medical and Veterinary) | 5,120 | Three Months Ended June 30, 2026 | — |
| Total Students (Walden) | 54,851 | Three Months Ended June 30, 2026 | — |
| Net leverage | 0.7 | Q3 FY2026 | — |
|
|
|||
| Adjusted EBITDA margin (Chamberlain) non-GAAP | 24.6% | Q2 FY2026 | — |
| Adjusted EBITDA margin (Walden) non-GAAP | 39.8% | Q2 FY2026 | — |
| Share repurchases | $165M | Q2 FY2026 | — |
| Total student enrollment | 97,010 | Q2 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Education & Training Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVSA
this stock
Covista Inc.
|
$4.50B | +27.5% | +9.3% | 18.8 | 4.9% |
|
EDU
New Oriental Education & Technology Group Inc.
|
$9.26B | +3.4% | +13.6% | — | 2.4% |
|
TAL
TAL Education Group
|
$6.93B | +11.1% | +33.7% | — | 3.3% |
|
LAUR
Laureate Education, Inc.
|
$5.29B | +14.0% | +19.5% | 17.5 | 2.1% |
|
LOPE
Grand Canyon Education, Inc.
|
$3.83B | -11.7% | +19.8% | 17.8 | 6.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVSA | +2.9% | +17.7% | +33.6% | +5.7% | +27.5% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +3.3% | +14.8% | +22.0% | +2.7% | +14.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.